Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Faith D. Watson"'
Autor:
Kevin Ronald Condroski, Kolakowski Gabrielle R, Thomas C. Irvin, Nisha A. Patel, Manoj Kumar, Joshua Ballard, Erin D. Anderson, Andrews Steven W, Eliana B. Gomez, Barbara J. Brandhuber, Faith D. Watson
Publikováno v:
Cancer Research. 81:1464-1464
In May 2020, selpercatinib became the first FDA-approved selective RET inhibitor, indicated for patients (pts) with RET fusion-positive NSCLC and thyroid cancer as well as RET-mutant medullary thyroid cancer. Despite the durable activity of selpercat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3835b3eb20997d91703b484b00e66cb
https://doi.org/10.1158/1538-7445.am2021-1464
https://doi.org/10.1158/1538-7445.am2021-1464
